springsumm
sever
observ
studi
canada
show
increas
risk
medicallyattend
laboratoryconfirm
ill
among
prior
recipi
trival
inactiv
influenza
vaccin
tiv
explanatori
hypothes
includ
direct
indirect
vaccin
effect
random
placebocontrol
ferret
studi
test
whether
prior
receipt
tiv
may
directli
influenc
ill
thirtytwo
ferret
group
receiv
ml
intramuscular
inject
canadianmanufactur
commerciallyavail
nonadjuv
split
fluvir
pb
placebo
day
day
anim
challeng
four
ferret
per
group
randomli
select
sacrific
day
postchalleng
rest
follow
sera
test
antibodi
vaccin
antigen
hemagglutin
inhibit
hi
microneutr
mn
nucleoproteinbas
elisa
microarray
assay
clinic
characterist
nasal
viru
titer
record
prechalleng
postchalleng
sacrific
lung
viru
titer
cytokin
inflammatori
score
determin
baselin
characterist
similar
two
group
anim
antibodi
rise
vaccin
antigen
evid
elisa
microarray
hi
mn
assay
viru
challeng
rais
antibodi
assay
group
begin
vaccin
anim
experienc
greater
loss
appetit
weight
placebo
anim
reach
greatest
betweengroup
differ
weight
loss
rel
baselin
vs
p
vaccin
anim
higher
lung
viru
titer
logmean
vs
respect
p
lung
inflammatori
score
vs
respect
p
cytokin
level
group
recov
find
systematicallyinfect
ferret
may
replic
human
experi
consid
conclus
explain
human
observ
ferret
find
consist
direct
advers
effect
prior
tiv
receipt
ill
warrant
indepth
investig
search
possibl
mechanist
explan
springsumm
sever
observ
studi
canada
report
prior
receipt
trival
inactiv
influenza
vaccin
tiv
associ
increas
risk
medicallyattend
laboratoryconfirm
ill
estim
risk
odd
ratio
compar
unvaccin
increas
risk
appar
among
vaccin
peopl
compar
hospit
commun
case
observ
studi
set
show
contradictori
result
includ
increas
null
protect
effect
vaccin
hypothes
explain
find
canada
initi
focus
methodolog
observ
design
productspecif
domesticallymanufactur
vaccin
consider
howev
randomizedcontrol
trial
rct
hong
kong
span
novemb
octob
also
show
significantli
increas
rel
risk
among
children
receiv
differ
manufactur
tiv
product
vaxigrip
sanofi
pasteur
lyon
franc
previou
ferret
studi
also
shown
mix
result
although
none
demonstr
tiv
protect
two
small
ferret
studi
report
tiv
effect
viru
replic
nasal
lung
specimen
clinic
outcom
assess
sever
studi
shown
consist
albeit
nonsignific
trend
toward
greater
weight
loss
worsen
sever
indic
vaccin
ferret
ferret
studi
date
howev
suffer
small
sampl
size
typic
compar
anim
per
group
total
mechanist
hypothes
explain
increas
risk
among
prior
tiv
recipi
includ
direct
indirect
vaccin
effect
direct
effect
hypothesi
postul
season
vaccin
may
directli
influenc
host
resist
pandem
viru
infect
andor
replic
wherea
indirect
hypothesi
propos
season
vaccin
may
block
robust
complex
crossprotect
immun
otherwis
afford
season
viru
infect
therebi
indirectli
increas
risk
pandem
ill
report
random
blind
placebocontrol
ferret
studi
test
whether
commerciallyavail
tiv
predominantli
use
canada
may
directli
influenc
diseas
risk
overview
experiment
procedur
conduct
laval
univers
anim
care
facil
april
juli
figur
anim
hous
two
per
cage
room
permit
food
water
ad
libitum
primari
outcom
studi
weight
loss
sampl
size
assign
test
differ
proportion
weight
loss
baselin
follow
infect
pandem
viru
base
power
alpha
detect
mean
differ
weight
loss
rel
baselin
placebo
group
vaccin
group
given
standard
deviat
sd
ferret
per
group
would
requir
use
ferret
per
group
thirtytwo
male
ferret
randomli
assign
receiv
ml
intramuscular
inject
either
tiv
vaccin
pb
placebo
day
studi
personnel
investig
remain
blind
vaccineplacebo
assign
throughout
experiment
procedur
assay
glaxosmithklin
gsk
fluvir
manufactur
laval
canada
sanofi
pasteur
vaxigrip
manufactur
lyon
franc
suppli
approxim
respect
season
split
tiv
distribut
canada
season
experi
therefor
use
domin
canadian
manufactur
commerciallyavail
nonadjuv
gsk
sodium
deoxychol
splitantigen
fluvir
contain
three
potenc
three
vaccin
strain
postexpiri
coldchain
maintain
fluvir
lot
use
confirm
singl
radial
immunodiffus
srid
test
center
biolog
evalu
research
unit
state
us
food
drug
administr
fda
us
specif
requir
mgml
hemagglutinin
ha
antigen
dose
ml
base
mean
three
test
addit
requir
around
standard
deviat
sd
last
assess
februari
antigen
mean
ha
content
tiv
lot
use
remain
mgml
sd
within
requir
specif
day
anim
lightli
anesthet
challeng
intranas
ml
tabl
administ
halfvolum
per
nostril
four
randomlyselect
ferret
per
group
sacrif
day
ie
day
postchalleng
remaind
sacrif
day
ie
day
postchalleng
preship
sera
collect
march
serum
sampl
anesthet
anim
collect
day
may
assess
antibodi
tiv
compon
haemagglutin
inhibit
hi
microneutr
mn
nucleoprotein
np
base
elisa
protein
microarray
assay
hemagglutin
inhibit
microneutralizationantigen
analys
refer
virus
use
hi
mn
assay
obtain
canada
influenza
refer
laboratori
nation
microbiolog
laboratori
nml
winnipeg
passag
mdck
cell
two
three
time
tabl
mdckpassag
virus
test
hi
mn
refer
ferret
antiserum
provid
nml
confirm
antigen
integr
maintain
rel
whorecommend
refer
virus
viral
hemagglutinin
ha
neuraminidas
na
also
sequenc
assess
amino
acid
aa
ident
rel
refer
virus
actual
vaccin
compon
select
manufactur
tabl
tabl
compar
respect
vaccin
strain
passag
assay
virus
show
complet
ha
na
ident
season
compar
challeng
viru
passag
assay
viru
also
show
ha
na
ident
percent
ident
reduc
expect
compar
season
pandem
strain
protein
hi
mn
assay
conduct
duplic
accord
establish
protocol
detail
individu
result
assign
geometr
mean
titer
gmt
duplic
valu
summari
hi
mn
serolog
statist
compar
includ
number
meet
threshold
titer
chang
titer
baselin
day
day
assess
seroconvers
group
gmt
confid
interv
ci
group
gmt
ratio
gmtr
haemagglutin
inhibit
method
prepar
hi
assay
sera
treat
receptor
destroy
enzym
accur
chemic
scientif
ny
remov
nonspecif
inhibitor
agglutin
hemadsorb
turkey
erythrocyt
lampir
biolog
laboratori
pennsylvania
sera
serial
dilut
begin
phosphat
buffer
salin
ml
serum
dilut
react
ml
antigen
infect
mdck
cell
lysat
supernat
contain
ha
unit
viru
minut
mixtur
ml
turkey
erythrocyt
ad
mix
prepar
incub
minut
result
record
photographi
hi
titer
design
invers
highest
dilut
detect
hi
activ
still
present
influenza
b
viru
use
hi
assay
ethertr
inactiv
form
briefli
clarifi
influenza
b
viru
cell
lysat
mix
agit
equal
volum
diethyl
ether
mixtur
kept
minut
allow
phase
separ
top
ether
layer
aspir
nitrogen
ga
bubbl
viru
prepar
remov
residu
ether
prepar
use
hi
assay
microneutr
method
mn
assay
tissu
cultur
infecti
dose
viral
titer
determin
mdck
cell
sera
treat
receptor
destroy
enzym
accur
chemic
scientif
ny
serial
dilut
serumfre
medium
megavir
hyclon
utah
begin
ml
dilut
infecti
unit
viru
ad
plate
incub
hour
allow
viru
antibodi
interact
content
well
transfer
onto
microtit
plate
confluent
monolay
mdck
cell
hour
incub
medium
well
remov
replac
fresh
megavir
medium
contain
mgml
chloromethyl
keton
tpck
treat
trypsin
plate
incub
monitor
cytopath
effect
day
mn
titer
defin
invers
serum
dilut
immedi
preced
well
cytopath
effect
protein
microarray
method
competit
elisa
conduct
sera
use
commerciallyavail
npbase
influenza
antibodi
test
kit
idexx
laboratori
inc
switzerland
competit
elisa
antibodi
valu
calcul
sampl
optic
densiti
od
divid
neg
control
od
ratio
consid
posit
mean
valu
ci
display
smaller
elisa
ratio
denot
higher
antibodi
level
protein
microarray
serolog
assay
conduct
studi
nonstudi
antigen
list
tabl
perform
previous
describ
adapt
detect
ferret
antibodi
serum
sampl
test
singl
dilut
blotto
contain
surfact
ampt
thermo
fisher
scientif
inc
rockford
usa
incub
step
one
hour
recombin
protein
spot
duplic
incub
ml
blotto
follow
ml
dilut
ferret
serum
twostep
conjug
incub
ml
mous
antimustelid
igg
antibodiesonlin
aachen
germani
follow
ml
dylight
goat
antimous
igg
jackson
immunoresearch
baltimor
pike
usa
blotto
contain
surfact
ampt
wash
dri
slide
scan
use
powerscann
tecan
nnedorf
switzerland
signal
quantifi
use
scanarray
scanner
perkin
elmer
waltham
usa
individu
spot
signal
valu
correct
subtract
per
spot
background
fluoresc
truncat
zero
signal
background
final
individu
per
ferret
valu
assign
averag
duplic
log
imput
valu
zero
valu
compar
antigen
studi
group
day
activ
rectal
temperatur
appetit
weight
record
daili
day
challeng
day
sacrific
baselin
refer
weight
per
ferret
comput
averag
day
weight
activ
score
one
alert
play
two
alert
play
induc
three
alert
play
stay
hide
place
four
neither
alert
play
five
human
endpoint
appetit
score
usual
diminish
appetit
viru
titer
assess
nasal
wash
prechalleng
day
daili
postchalleng
sacrific
whole
right
lung
homogen
schedul
sacrific
viru
titer
determin
standard
plaqu
assay
use
mdck
cell
express
log
plaqueform
unit
pfu
per
ml
paraffin
tissu
section
prepar
whole
left
lung
ferret
histopatholog
assess
schedul
sacrific
inflamm
grade
six
indic
bronchialendobronchi
peribronchi
perivascular
interstiti
pleural
intraalveolar
score
normal
mild
moder
mark
maximum
combin
score
vascular
congest
pulmonari
edema
similarli
score
lung
immunohistochemistri
undertaken
identifi
cell
viru
antigen
paraffin
tissu
section
quench
minut
aqueou
h
pretreat
proteinas
k
minut
dilut
mous
monoclon
antibodi
influenza
nucleoprotein
inhous
appli
one
hour
section
visual
use
horseradish
peroxidaselabel
polym
envisionhsystem
antimous
dako
usa
react
chromogen
diaminobenzidin
counterstain
gill
hematoxylin
chang
lung
cytokin
mrna
gene
express
assess
rel
quantit
pcr
qpcr
rna
extract
ml
right
lung
homogen
use
qiaamp
viral
rna
minikit
revers
transcript
perform
use
high
capac
rnatocdna
kit
appli
biosystem
mg
total
rna
follow
manufactur
protocol
qpcr
perform
use
taqmanh
gene
express
master
mix
abi
primer
design
target
publish
cytokin
sequenc
mustela
putoriu
furo
mrna
sequenc
final
concentr
mm
assay
run
stepon
plu
abi
follow
condit
minut
minut
follow
cycl
second
minut
foldchang
calcul
use
deltadelta
ct
method
uninfect
ferret
refer
gapdh
endogen
control
chisquar
fisher
exact
test
use
compar
categor
variabl
ttest
wilcoxon
method
continu
variabl
weight
nasal
viru
titer
protein
microarray
valu
analys
via
contrast
mixedeffect
linear
model
group
visit
interact
repeat
measur
anim
protein
microarray
valu
analys
repeat
exclud
statist
outlier
without
substant
affect
main
conclus
inflammatori
score
individu
ferret
present
combin
inflammatori
score
cytokin
valu
versu
compar
via
contrast
twoway
anova
model
group
schedul
sacrific
day
interact
observ
describ
signific
attempt
made
correct
multipl
infer
individu
hi
mn
elisa
assay
result
display
concurr
preship
day
time
point
four
vaccin
four
placebo
anim
sacrif
tabl
anim
per
group
sacrif
day
tabl
vaccin
anim
tabl
placebo
anim
summari
elisa
result
shown
tabl
summari
microarray
result
studi
antigen
figur
studi
nonstudi
antigen
crossreact
respons
shown
figur
summari
hi
mn
statist
shown
tabl
tabl
respect
anim
confirm
npbase
elisa
influenza
preship
day
day
signific
elisa
antibodi
rise
follow
immun
vaccin
group
antibodi
rise
evid
day
challeng
vaccin
anim
day
placebo
ferret
tabl
tabl
tabl
tabl
ultim
total
influenza
elisa
antibodi
significantli
higher
among
vaccin
compar
placebo
anim
schedul
sacrific
tabl
protein
microarray
result
consist
elisa
addit
show
vaccineinduc
antibodi
season
antigen
valu
significantli
higher
vaccin
anim
rel
preimmun
compar
placebo
day
pronounc
day
first
tiv
dose
ie
three
week
twodos
vaccin
seri
complet
figur
signific
rise
antibodi
rel
preimmun
vaccin
compon
day
rel
placebo
group
day
ie
five
week
vaccin
seri
complet
slight
signific
decreas
antibodi
evid
day
postimmun
compar
baselin
thereaft
rel
placebo
call
question
clinic
relev
signific
rise
antibodi
rel
preimmun
evid
day
vaccin
placebo
group
interest
infect
induc
antibodi
day
also
close
relat
antigen
studi
group
significantli
higher
latter
vaccin
figur
furthermor
day
among
vaccin
among
placebo
anim
challeng
induc
significantli
greater
crossreact
nonstudi
variant
anim
never
expos
evid
rel
preimmun
placebo
group
prechalleng
day
figur
increas
follow
challeng
among
vaccin
evid
day
nonvaccin
antigen
rel
preimmun
rel
placebo
anim
also
shown
hi
mn
assay
influenza
preship
tabl
tabl
tabl
variabl
hi
mn
antibodi
titer
evid
thereaft
overal
howev
signific
rise
vaccineinduc
antibodi
shown
elisa
protein
microarray
day
evid
hi
mn
assay
except
among
vaccin
ferret
tabl
tabl
convers
ferret
group
show
substanti
neutral
antibodi
day
tabl
tabl
high
gmt
gmtr
rel
baselin
slightli
nonsignificantli
higher
placebo
compar
vaccin
group
hi
mn
tabl
tabl
averag
baselin
weight
compar
vaccin
kg
placebo
kg
group
p
begin
vaccin
anim
show
diminish
appetit
compar
placebo
recipi
versu
p
greatest
betweengroup
differ
versu
p
resolv
vs
p
greatest
betweengroup
differ
appetit
vs
p
weight
loss
baselin
greater
vaccin
placebo
group
evid
begin
margin
signific
across
full
studi
period
weight
loss
p
absolut
loss
p
figur
greatest
betweengroup
differ
percentag
weight
loss
baselin
vs
p
figur
day
vaccin
versu
placebo
anim
lost
bodi
weight
compar
baselin
p
tabl
tabl
tabl
consist
random
select
pattern
evid
regardless
sacrific
day
mean
percentag
weight
loss
baselin
vaccin
group
placebo
group
among
anim
select
sacrific
respect
among
anim
sacrif
instead
anim
compar
score
one
alertnessplay
time
point
except
activ
level
margin
wors
score
two
anim
group
temperatur
pattern
differ
vaccin
placebo
group
peak
meanmedian
temperatur
respect
nasal
titer
differ
significantli
group
time
p
nasal
viru
titer
rose
steepli
vaccin
versu
placebo
group
mean
differ
logtitr
versu
pfuml
p
fell
steepli
mean
differ
logtitr
versu
pfuml
p
figur
lung
titer
significantli
higher
vaccin
versu
placebo
group
logmean
versu
pfu
ml
p
figur
neither
group
detect
viru
lung
anim
sacrif
vaccin
group
higher
combin
meanmedian
lung
inflammatori
score
placebo
anim
versu
differ
reach
statist
signific
p
tabl
two
four
vaccin
anim
show
combin
lung
inflammatori
score
compar
none
four
placebo
anim
maximum
score
tabl
salient
histolog
featur
shown
figur
anim
group
highest
lowest
combin
inflammatori
score
illustr
sever
bronchopneumonia
evid
half
vaccin
none
placebo
anim
increas
micrometr
scale
panel
reflect
patholog
chang
mark
diffus
best
render
low
magnif
wherea
mild
moder
focal
chang
panel
c
necessit
photomicrograph
higher
magnif
compar
combin
mean
lung
inflammatori
score
significantli
lower
vaccin
group
among
anim
sacrif
vs
p
wherea
show
littl
chang
time
placebo
group
vs
p
signific
interact
schedul
sacrific
day
group
p
combin
meanmedian
lung
inflammatori
score
significantli
differ
vaccin
versu
placebo
group
versu
vaccin
placebo
group
influenza
antigen
detect
immunostain
bronchial
bronchiolar
epithelium
within
alveolar
wall
posit
cell
identifi
pneumocyt
use
doubl
immunolabel
shown
occasion
cell
morpholog
macrophag
viral
antigen
detect
anim
ifn
gamma
limit
detect
group
schedul
sacrific
lung
cytokin
consist
nonsignificantli
higher
vaccin
versu
placebo
group
cytokin
valu
lower
group
consist
nonsignificantli
lower
vaccin
anim
versu
differ
statist
signific
vaccin
group
cytokin
p
except
ifn
alpha
wherea
differ
signific
placebo
group
except
p
overal
interact
schedul
sacrific
day
studi
group
signific
cytokin
figur
springsumm
sever
observ
studi
canada
report
prior
recipi
tiv
experienc
approxim
twofold
increas
risk
medicallyattend
laboratoryconfirm
ill
recogn
observ
design
suscept
methodolog
bia
gold
standard
rct
analysi
would
typic
consid
essenti
clarifi
unexpect
find
hong
kong
rct
tiv
vaxigrip
alreadi
underway
shown
similar
associ
among
vaccin
children
signific
rel
risk
increas
adjust
season
infect
howev
followup
rct
use
vaxigrip
span
august
decemb
investig
instead
report
signific
protect
effect
rct
lack
suffici
power
analysi
base
virologicallyconfirm
infect
conclus
drawn
instead
less
reliabl
serologicallydefin
outcom
rct
test
associ
human
becom
practic
imposs
given
sinc
fall
season
tiv
routin
contain
protect
homolog
antigen
therefor
undertook
rct
evalu
possibl
direct
effect
prior
heterolog
tiv
receipt
diseas
risk
ferret
ideal
altern
model
human
influenza
infect
although
none
anim
becam
moribund
sever
ill
requir
euthanasia
ferret
immun
two
dose
tiv
show
significantli
wors
clinic
virolog
patholog
featur
follow
pandem
infect
compar
placebo
recipi
origin
power
show
vaccin
anim
experienc
significantli
greater
weight
loss
rel
baselin
follow
infect
maxim
differ
placebo
nasal
wash
titer
differ
vaccin
anim
show
significantli
higher
lung
viru
titer
consist
lung
viru
find
lung
inflamm
also
increas
vaccin
compar
placebo
anim
although
fewer
anim
sacrif
day
differ
fell
short
statist
signific
inflammatori
indic
howev
significantli
higher
compar
vaccin
anim
show
chang
across
period
placebo
recipi
lung
cytokin
show
similar
pattern
although
ill
activ
level
appear
similar
group
base
categori
induc
play
may
insuffici
resolut
reflect
clinic
differ
lung
diseas
manifest
otherwis
signific
loss
appetit
weight
day
postchalleng
anim
group
recov
human
studi
doubl
risk
medicallyattend
pandem
ill
observ
among
tiv
recipi
increas
risk
hospit
shown
broadli
interpret
suggest
increas
risk
acquir
infect
per
se
wherea
report
increas
diseas
sever
among
systematicallyinfect
ferret
find
ferret
may
replic
experi
human
worth
note
howev
sourc
popul
human
observ
studi
patient
seek
medic
care
although
ill
sever
among
outpati
visit
specif
compar
vaccin
unvaccin
particip
subject
experienc
influenzalik
ill
sever
enough
prompt
medic
consult
within
one
week
ill
onset
outcom
significantli
increas
among
vaccin
regard
pattern
acut
worsen
ill
first
week
infect
vaccin
ferret
follow
subsequ
recoveri
day
consist
increas
outpati
hospit
risk
observ
vaccin
human
ferret
rct
suggest
earlier
find
observ
studi
human
dismiss
basi
methodolog
bia
alon
direct
mechanist
explan
sought
whether
find
may
productspecif
may
also
appli
tiv
product
yet
separ
assess
followup
studi
date
hypothes
biolog
mechan
explain
increas
risk
among
prior
tiv
recipi
includ
direct
indirect
vaccin
effect
indirect
mechan
includ
infect
block
hypothesi
wherebi
effect
season
vaccin
may
prevent
robust
complex
crossprotect
immun
heterolog
virus
afford
season
infect
cellmedi
respons
conserv
intern
viru
compon
epidemiolog
investig
favour
hypothesi
relat
variat
temporari
immun
hypothesi
appendix
g
origin
public
demonstr
indirect
hypothes
insuffici
implaus
fulli
explain
doubl
risk
requir
unreason
high
estim
infect
attack
rate
infectioninduc
crossprotect
tiv
effect
test
whether
increas
risk
vaccine
may
occur
without
invok
infect
block
mechan
specif
design
current
ferret
experi
without
intermediari
heterolog
season
influenza
infect
rule
addit
role
indirect
vaccin
effect
mediat
infect
block
mechan
show
direct
vaccin
effect
like
least
contribut
previou
find
possibl
direct
vaccin
effect
includ
antibodydepend
enhanc
ade
wherebi
viru
uptak
cell
enhanc
presenc
lowlevel
crossreact
nonneutr
antibodi
best
describ
dengu
possibl
role
crossreact
antibodi
explain
sever
manifest
otherwis
healthi
adult
archiv
lung
section
fatal
adult
case
pandem
previous
suggest
anoth
recent
studi
report
associ
higher
ratio
crossreact
elisa
versu
neutral
antibodi
titer
earli
infect
sever
ill
enhanc
respiratori
diseas
vaccin
swine
also
report
follow
challeng
heterolog
homosubtyp
virus
share
crossreact
neutral
antibodi
ferret
experi
clinic
worsen
vaccin
swine
evid
two
five
day
postchalleng
correl
elev
proinflammatori
cytokin
respons
lung
unlik
current
ferret
prior
human
studi
howev
swine
studi
use
adjuv
whole
virion
vaccin
addit
heterosubtyp
neuraminidas
surfac
protein
ie
versu
relev
uncertain
ade
classic
associ
enhanc
viru
uptak
macrophag
fcreceptorbear
cell
demonstr
vitro
influenza
recent
also
specif
presenc
heterolog
human
antisera
vaccin
ferret
higher
lung
viru
titer
observ
immunohistochemistri
could
distinguish
affect
cell
lung
vaccin
versu
placebo
anim
macrophag
predomin
either
group
recent
swine
howev
heterolog
antibodi
shown
enhanc
infect
mammalian
mdck
cell
describ
context
fusionenhanc
crossreact
stalk
antibodi
absent
neutral
antibodi
target
globular
head
experi
unabl
elucid
put
immunolog
mechan
identifi
signific
vaccineinduc
influenza
antibodi
rise
elisa
confirm
includ
antibodi
respons
season
tiv
compon
also
rapid
signific
increas
influenza
elisa
antibodi
follow
challeng
among
vaccin
placebo
ferret
sacrif
neutral
antibodi
evid
either
group
lower
neutral
antibodi
even
among
vaccin
versu
placebo
ferret
although
statist
signific
consist
human
immunogen
trial
show
blunt
pandem
vaccineinduc
respons
associ
prior
season
vaccin
receipt
convers
pandem
immun
observ
boost
preexist
heterosubtyp
antibodi
may
also
consist
find
tiv
compon
broad
boost
crossreact
antibodi
antigenicallydist
variant
observ
protein
microarray
vaccin
placebo
anim
although
protein
microarray
show
crossreact
antibodi
prior
design
detect
sort
stalk
antibodi
highlight
associ
sever
diseas
vaccin
swine
ultim
therefor
unabl
discern
whether
rise
elisa
antibodi
vaccin
anim
suggest
earli
crossreact
nonneutr
antibodi
antibodi
increas
tiv
antigen
week
second
dose
although
microarray
indic
latter
certainli
contribut
tcell
hyporespons
may
altern
explan
compat
hypothesi
direct
vaccin
effect
phenomenon
report
sameseason
influenza
vaccin
boosterdos
studi
parallel
also
allergi
literatur
suggest
peptideinduc
tcell
hyporespons
begin
week
last
week
howev
ferret
placebo
inflammatori
score
indic
mildminim
peribronchi
inflamm
b
ferret
vaccin
inflammatori
score
indic
mildminim
perivascular
inflamm
c
ferret
placebo
inflammatori
score
indic
moder
bronchial
mild
peribronchialperivascular
inflamm
ferret
vaccin
inflammatori
score
indic
sever
bronchopneumonia
increas
micrometr
scale
panel
reflect
patholog
chang
mark
diffus
best
render
low
magnif
wherea
mild
moder
focal
chang
panel
c
necessit
photomicrograph
higher
magnif
correspond
histopatholog
score
shown
tabl
interferongamma
detect
limit
group
lung
cytokin
vaccin
ferret
otherwis
consist
nonsignificantli
higher
compar
placebo
anim
notabl
includ
proinflammatori
regulatori
cytokin
implic
superinduc
neutrophil
infiltr
acut
lung
immunopatholog
follow
influenza
infect
counteract
dampen
interact
earlier
canadian
ferret
experi
anim
administ
singl
dose
tiv
also
experienc
wors
ill
nasal
wash
substanti
rais
fluvir
group
significantli
flumist
group
diseas
enhanc
suggest
vaccin
group
compar
control
assess
nasal
wash
cytokin
flumist
statist
power
explor
cytokin
differ
lung
also
nonsignificantli
rais
fluvir
versu
placebo
ferret
cytokin
valu
lower
absenc
lung
patholog
howev
none
betweengroup
cytokin
differ
either
time
point
statist
signific
limit
studi
although
ferret
consid
ideal
anim
model
human
influenza
infect
anticip
differ
immunolog
clinic
aspect
immun
infect
ill
respons
time
dose
intens
across
speci
overal
pattern
may
compar
ferret
studi
support
precis
quantif
actual
risk
human
greater
likelihood
sever
diseas
base
sever
clinic
indic
weight
loss
lung
viru
titer
among
vaccin
compar
unvaccin
ferret
may
replic
greater
likelihood
medicallyattend
ill
previous
report
vaccin
human
use
systemat
infect
ferret
clear
differ
human
experi
respect
precondit
influenza
exposur
histori
immunolog
context
process
infect
acquisit
relev
paramet
vaccin
immunogen
clinic
outcom
monitor
clinic
relev
differ
report
vaccin
placebo
ferret
ultim
best
interpret
context
studi
object
assign
follow
prior
human
observ
report
main
object
ferret
studi
assess
random
control
design
whether
prior
receipt
tiv
may
direct
advers
effect
ill
specif
power
relat
weight
loss
although
precis
elucid
underli
mechan
involv
current
ferret
studi
support
hypothesi
direct
vaccin
effect
taken
togeth
prior
human
swine
studi
find
repres
signal
warrant
investig
better
understand
though
consid
conclus
promin
concern
ferret
studi
may
relat
failur
show
neutral
antibodi
respons
vaccin
issu
therefor
consid
detail
observ
greater
albeit
lowlevel
variabl
antibodi
titer
hi
nonfunct
assay
microneutr
npbase
elisa
intraand
interlaboratori
variabl
antibodi
assay
result
wellrecogn
thu
interpret
find
context
combin
hi
mn
elisa
result
overal
indic
anim
preship
baselin
vaccineinduc
hi
mn
respons
evid
thereaft
signific
vaccineinduc
antibodi
rise
shown
npbase
elisa
protein
microarray
assay
latter
also
shown
high
serumlow
antibodi
concentr
ie
test
dilut
although
srid
test
expir
vaccin
lot
use
still
met
standard
ha
potenc
requir
annual
commerci
vaccin
approv
fda
rule
unrecogn
vaccin
chang
time
may
influenti
mdckpassag
virus
use
hi
mn
assay
antigen
equival
refer
strain
amino
acid
sequenc
show
also
ident
ha
na
vaccin
compon
argu
linear
differ
explain
suboptim
neutral
respons
measur
howev
rule
conform
chang
protein
structur
origin
vaccin
compris
sodiumdeoxychol
disrupt
inactiv
viru
viru
use
assay
also
antigen
equival
whorecommend
refer
viru
share
ha
antigen
site
amino
acid
ident
howev
conduct
antigen
test
relat
actual
vaccin
compon
use
manufactur
rule
differ
assay
vaccin
virus
suboptim
vaccin
respons
measur
tabl
protein
microarray
also
show
variabl
lowlevel
respons
compon
among
immun
ferret
day
significantli
greater
placebo
compar
preimmun
day
ie
five
week
second
vaccin
dose
whether
latter
due
antibodi
rise
time
follow
immun
crossreact
respons
follow
challeng
unknown
howev
similar
effect
observ
rel
placebo
nonvaccin
subtyp
virus
includ
microarray
suggest
vaccin
respons
threshold
defin
antibodi
respons
also
anticip
vari
across
speci
assay
ferret
variou
antigen
assay
use
fact
seroprotect
threshold
yet
establish
ferret
assay
howev
failur
induc
robust
hi
mn
antibodi
respons
inactiv
influenza
vaccin
ferret
long
recogn
singl
sever
dose
absenc
prior
infect
adjuv
season
novel
pandem
vaccin
order
replic
close
observ
human
use
commerci
avail
nonadjuv
fluvir
lot
administ
canada
note
human
studi
conduct
product
pediatr
elderli
mous
studi
conduct
fluvir
also
induc
suboptim
hi
andor
mn
respons
season
vaccin
antigen
exampl
pediatr
trial
includ
infant
toddler
month
age
similarli
influenza
ferret
schedul
two
ml
dose
thimerosalfre
version
fluvir
induc
significantli
lower
antibodi
respons
even
half
volum
ml
per
dose
vaxigrip
similar
pattern
though
less
pronounc
also
observ
compon
reason
diminish
immunogen
canadian
vaccin
unknown
although
author
pediatr
trial
propos
complet
clearanc
intact
viru
among
possibl
explan
human
observ
studi
tiv
still
shown
protect
overal
homolog
season
influenza
springsumm
observ
increas
risk
heterolog
ill
identifi
six
month
tiv
receipt
regard
lower
vaccineinduc
antibodi
titer
ferret
threeweek
postimmun
challeng
time
point
may
better
replic
endofseason
antibodi
condit
vaccin
human
expos
viru
prior
ferret
studi
assess
fluvir
also
suggest
diseas
enhanc
abl
induc
homolog
hi
antibodi
respons
compon
mean
antibodi
titr
exceed
within
two
week
singl
ml
vaccin
dose
higher
even
induc
pediatr
studi
popul
cite
variabl
serolog
respons
may
reflect
lottolot
laboratori
differ
know
precis
mechan
involv
vaccineassoci
enhanc
respiratori
diseas
unabl
exactli
know
replic
human
immunolog
context
springsumm
adjust
human
vaccin
formul
dose
schedul
forc
higher
ferret
vaccin
respons
instead
focus
clinic
paramet
record
observ
effect
accord
standard
immun
practic
gener
ferret
studi
date
suffer
small
sampl
size
insuffici
power
studi
power
clinic
percentag
weight
loss
comparison
followup
day
postchalleng
failur
reach
statist
signific
consist
indic
prompt
dismiss
stimul
investig
may
argu
lung
find
chanc
occurr
among
ferret
poorlyrepres
full
group
experi
howev
anim
group
randomli
blindli
select
sacrific
comparison
baselin
characterist
show
signific
withingroup
differ
accord
schedul
endpoint
lung
find
vaccin
anim
higher
viru
titer
lung
inflamm
consist
overal
clinic
pattern
greater
loss
appetit
weight
nevertheless
futur
experi
power
anim
specif
examin
earli
acut
clinic
immunolog
patholog
find
explor
possibl
mechan
greater
detail
assess
anim
wherea
human
young
children
prior
potenti
crossattenu
influenza
infect
histori
use
anim
previou
swine
current
ferret
studi
may
relev
increas
sever
highlight
vaccin
anim
lesser
extent
note
associ
peopl
experi
need
explor
nuanc
relat
infect
andor
immun
histori
addit
various
complic
human
experi
recent
public
diseas
enhanc
includ
among
possibl
hypothes
explain
greater
pandem
morbid
america
compar
australia
new
zealand
europ
refer
find
vaccin
swine
interpret
ecolog
context
region
differ
prior
heterolog
season
viru
circul
given
find
vaccin
ferret
swine
howev
region
differ
prior
heterolog
season
vaccin
ie
tiv
coverag
may
also
relev
consid
note
mechan
ade
explanatori
requir
precis
balanc
lowlevel
crossreact
nonneutr
antibodi
manifest
particular
slide
immunolog
scale
may
captur
anim
human
time
exposur
spectrum
ill
anticip
infect
process
greater
likelihood
sever
requir
expos
individu
experi
outcom
howev
addit
immunolog
complex
relat
ade
involv
may
contribut
variabl
clinic
outcom
observ
among
vaccin
ferret
variabl
report
associ
human
experi
assess
uniqu
context
heterolog
homosubtyp
pandem
challeng
suggest
origin
antigen
sin
aspect
crossreact
nonneutr
antibodi
requir
ade
appli
antigen
differ
less
exist
across
relat
distinct
primeboost
strain
amino
acid
differ
season
pandem
antigen
within
rang
similar
tabl
much
closer
homolog
across
amino
acid
differ
across
residu
howev
without
better
understand
underli
mechan
specif
virolog
interact
specul
whether
associ
could
appli
emerg
heterolog
heterosubtyp
variant
antigen
distanc
criteria
requir
defin
forecast
likelihood
remain
unknown
summari
although
ferret
find
consid
conclus
explain
earlier
human
observ
canada
support
hypothesi
prior
receipt
tiv
may
direct
advers
effect
ill
human
ferret
find
canada
consist
observ
elsewher
enhanc
diseas
follow
heterolog
influenza
challeng
vaccin
swine
given
potenti
implic
inform
influenza
immunoepidemiolog
public
health
respons
emerg
virus
signal
warrant
indepth
evalu
search
possibl
mechanist
explan
figur
microarray
valu
studi
nonstudi
antigen
group
studi
day
tabl
amino
acid
sequenc
substitut
hemagglutinin
ha
neuraminidas
na
mdckpassag
assay
challeng
virus
pdf
tabl
pairwis
ident
number
amino
acid
mutat
influenza
hemagglutinin
peptid
antigen
site
across
virus
use
antibodi
assay
challeng
pdf
